Almac Adds Simple Solutions to Bridge the Gap Between Clinical and Commercial Packaging
Addressing client demand to ease the transition between clinical and commercial launch for blister products, Almac a leading provider in clinical and commercial contract packaging to the global pharmaceutical and biotech industries has added new blistering technology at its US commercial packaging facility in Audubon, PA.
The Klockner EAS blister line can produce a range of blister formats processing both thermoform and coldform materials. This provides simple solutions for client packaging projects requiring low volume runs for evaluation of different packaging material combinations and cost effective stability packaging.
David Moore, Director of Operations at the Audubon facility explains: “Almac is offering seamless services from clinical supply, packaging development/design and stability testing to final commercial pack from its two Pennsylvania sites. Clients can now easily transition from the clinical blister presentation though various development packs, with Almac providing all the associated stability services.”
The addition of a further blister line complements the already impressive array of clinical and commercial packaging capabilities of blistering, bottling, walleting and vial/ampoule labelling available at Almac.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.